Propanc Biopharma, Inc. (PPCB): debt financing — Propanc Biopharma enters $25K convertible note and $13K AUD loan for working capital

Propanc Biopharma, Inc.

Issued $25,000 convertible note to Geebis Consulting at 8% interest; maturity June 2026; conversion price $5.00.
Note sold at $22,500 (10% OID); prepayment options with premiums from 110% to 125% within first 180 days.
Received $13,188 AUD loan from board member at 12% interest, maturing June 30, 2025.
Proceeds from both financings will be used for general working capital purposes.
Note is subject to 4.99% beneficial ownership limitation; conversion price adjusts on default.

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.99

Propanc Biopharma, Inc. incurred loan of $13,188 AUD with one of our members of the Board of Directors (the “Board Member”) at 12% per annum maturing June 30, 2025.

Instrument: loan
Principal: $13,188 AUD
Counterparty: one of our members of the Board of Directors (the “Board Member”)
Rate: 12% per annum
Maturity: June 30, 2025
Event: incurrence

Exact text from the filing

Effective Junel 13, 2025, the Company entered into and closed a loan agreement (the “Loan”) with one of our members of the Board of Directors (the “Board Member”), pursuant to which the Board Member loaned the Company an aggregate principal amount of $13,188 AUD.

View on SEC.gov

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.99

Propanc Biopharma, Inc. incurred convertible notes of $25,000 with an investor at 8% per annum maturing June 12, 2026.

Instrument: convertible notes
Principal: $25,000
Counterparty: an investor
Rate: 8% per annum
Maturity: June 12, 2026
Event: incurrence

Exact text from the filing

Effective June 12, 2025, Propanc Biopharma, Inc. (the “Company”) entered into and closed a securities purchase agreement (the “Purchase Agreement”) with an investor (the “Investor”), pursuant to which the Investor agreed to purchase a convertible promissory note from the Company in the aggregate principal amount of $25,000 (the “Note”), for a purchase price of $22,500.

View on SEC.gov

10 debt financings filed in the last 30 days. Browse all debt financings →

Propanc Biopharma, Inc. filing history →

Source: SEC EDGAR

accession 0001641172-25-015642

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.